Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.47 |
| ▸ | CNR2 | P34972 | 4/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | VDR | P11473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7250657 | 0.87 | CNR1 (0.44) | CNR1CNR2ESR1DRD2ALDH1A1 | |
| SCHEMBL3537131 | 0.85 | CNR2 (0.44) | CNR1CNR2DRD2ALDH1A1TNF | |
| SCHEMBL6086103 | 0.84 | FFAR1 (0.46) | CNR1CNR2ESR1VDRALDH1A1 | |
| SCHEMBL3537531 | 0.80 | CNR1 (0.44) | CNR1CNR2ALDH1A1KDM4E | |
| SCHEMBL3486832 | 0.79 | CNR1 (0.47) | CNR1CNR2MEN1KMT2AMAOB | |
| SCHEMBL18831747 | 0.79 | ESR1 (0.44) | CNR2ESR1DRD2VDRALDH1A1 | |
| SCHEMBL6905585 | 0.77 | CYP19A1 (0.44) | CNR1CNR2ESR1VDRKDM4E | |
| SCHEMBL1831814 | 0.77 | KMT2A (0.45) | CNR1CNR2ALDH1A1KDM4EMEN1 | |
| SCHEMBL4677396 | 0.77 | CNR1 (0.42) | CNR1CNR2ESR1 | |
| SCHEMBL1809731 | 0.77 | GRIN2D (0.49) | CNR1CNR2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026487-B2 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, a pyridyl group and an alkyl group, having retinoid-like biological activity | ALLERGAN, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20040097733-A1 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity | BEARD RICHARD L (US) | 2004-05-20 | — | — | US | disclosed |
| US-20030166932-A1 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity | ALLERGAN SALES, INC. | 2003-09-04 | — | — | US | disclosed |
| US-6613917-B1 | Retinoid agonist, antagonist or negative hormone-like biological activity | ALLERGAN, INC. | 2003-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166932-A1 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity | NR4A1, NR2E3, NR0B1 | CNR1 354/4885CNR2 811/4885ESR1 149/4885 |
| US-20040097733-A1 | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity | NR4A1, NR2E3, NR0B1 | CNR1 354/4885CNR2 811/4885ESR1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.